2018 Full year and fourth quarter
We announced our 2018 full year and fourth quarter results on Wednesday 06 February.
2011 Third Quarter - released 26 October 2011
Simon Dingemans, CFO, discusses our third quarter results 2011.
- Underlying sales growth of 6% and reported sales growth of 3%
- EPS before major restructuring 28.5p, dividend 17p (up 6%)
- Strong contribution from Japan: sales +57%
2011 Second Quarter - released 26 July 2011
Andrew Witty, CEO, and Simon Dingemans, CFO, discuss our second quarter results 2011.
- Q2 reported sales -2%
- EPS before major restructuring* 25p
- Underlying sales growth of 5%
- Increased pipeline visibility and dividend of 16p, up 7%
2011 First Quarter - released 27 April 2011
Andrew Witty, CEO, discusses our first quarter results 2011.
- Reported sales -10%, underlying sales +4%
- EPS before major restructuring 32.2p (+9%), dividend 16p (+7%)
2010 Fourth Quarter - released 03 February 2011
Andrew Witty, CEO, discusses our fourth quarter results 2010.
Other key information
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
Keep up to date with our news and recent announcements
A snapshot of our medicines and vaccines currently in development across three stages: phase I, phase II and phase III